GHK-Cu vs AHK-Cu: what the evidence supports
Evidence summary: No direct human head-to-head trial of GHK-Cu and AHK-Cu was identified. GHK-Cu has topical wound and broad preclinical literature; AHK-Cu has one PubMed-indexed ex-vivo human hair-follicle study. The evidence bases are unequal and do not validate combining the compounds or injecting either one.
Key findings
- No direct GHK-Cu versus AHK-Cu trial exists.
- AHK-Cu evidence is limited primarily to an ex-vivo follicle model.
- Neither compound has validated injectable human evidence.
A structural comparison is not an outcome comparison
GHK and AHK differ at the N-terminal residue, but that difference does not by itself establish different tissue targeting, receptor affinity or complementary effects. Those claims require direct experiments.
Product names should also distinguish free peptides from their copper complexes and report the applicable molecular-mass basis.
GHK-Cu evidence
GHK-Cu has decades of cell, animal and topical formulation research. Human evidence includes an older positive diabetic-ulcer subgroup and a null venous-ulcer trial, making route, formulation and study population essential context.
Review articles summarize many proposed pathways, but pathway counts should not be presented as established clinical benefits.
AHK-Cu evidence
Pyo and colleagues studied AHK-Cu in cultured human dermal-papilla cells and ex-vivo hair follicles. The study reported follicle elongation and cell-proliferation endpoints at very low concentrations.
This isolated-tissue work is not an in-vivo human trial. No registered human clinical evidence or direct comparison with GHK-Cu was identified.
Evidence-led selection
Choose a material according to the model and endpoint, not an unsupported ranking. Include free-peptide and copper-complex controls when copper coordination is part of the hypothesis.
Do not infer that a report for one product, strength or lot covers the other compound.
Continue to the full evidence guide
Read the GHK-Cu identity and evidence guide
Frequently asked questions
Which has more human evidence?
GHK-Cu has limited topical human trial evidence; AHK-Cu has ex-vivo human follicle evidence but no identified in-vivo clinical trial.
Have they been compared directly?
No direct human head-to-head study was identified.
Are combined effects proven?
No controlled study was identified that validates a GHK-Cu and AHK-Cu combination.
Primary references
- Pickart L, Vasquez-Soltero JM. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. PubMed 26236730
- Mulder GD, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair Regen. 1994. PubMed 17147644
- Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. PubMed 17703734
Related research materials
Research Use Only. Not for human or veterinary use. This page is not dosing or medical guidance.
